Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?

Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting

(2012) Camilo Rojas et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Serotonin receptor 3A polymorphism c.-42C > T is associated with severe dyspepsia

(2011) Suhreta Mujakovic et al.   BMC Medical Genetics

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype

(2011) K R Crews et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Heterogeneity Amongst 5-HT3 Receptor Subunits: Is this Significant?

(2011) N. Yaakob et al.   CURRENT MOLECULAR MEDICINE

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

(2011) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutics of 5-HT3 receptor antagonists: Current uses and future directions

(2011) Tina K. Machu   PHARMACOLOGY & THERAPEUTICS

Update and new trends in antiemetic therapy: the continuing need for novel therapies

(2010) P. Feyer et al.   ANNALS OF ONCOLOGY

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

(2010) F. Roila et al.   ANNALS OF ONCOLOGY

Polymorphism inHTR3Dshows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy

(2010) Christian Hammer et al.   PHARMACOGENOMICS

Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron

(2010) M V Tzvetkov et al.   PHARMACOGENOMICS JOURNAL

Functional characterization of a -100_-102delAAG deletion-insertion polymorphism in the promoter region of the HTR3B gene

(2009) Cornelia Meineke et al.   Pharmacogenetics and Genomics

Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy

(2008) P. A. Fasching et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Serotonin and GI clinical disorders

(2008) Robin Spiller   NEUROPHARMACOLOGY

Investigation ofHTR3Cmutations for association with 5HT3receptor antagonist anti-emetic efficacy

(2008) Michael B Ward et al.   PHARMACOGENOMICS

Cytochrome P450 and Chemical Toxicology

(2007) F. Peter Guengerich   CHEMICAL RESEARCH IN TOXICOLOGY